Connor Clark & Lunn Investment Management Ltd. Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Connor Clark & Lunn Investment Management Ltd. increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 22.4% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 73,320 shares of the biopharmaceutical company's stock after buying an additional 13,422 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.06% of Alnylam Pharmaceuticals worth $20,165,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Souders Financial Advisors grew its stake in Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company's stock worth $853,000 after buying an additional 36 shares in the last quarter. Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Lindbrook Capital LLC raised its position in Alnylam Pharmaceuticals by 11.1% during the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company's stock valued at $157,000 after purchasing an additional 57 shares in the last quarter. V Square Quantitative Management LLC raised its position in Alnylam Pharmaceuticals by 21.9% during the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company's stock valued at $81,000 after purchasing an additional 60 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 54.2% during the second quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded down $0.39 during trading on Thursday, hitting $248.40. The company's stock had a trading volume of 76,568 shares, compared to its average volume of 875,537. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a fifty day simple moving average of $273.83 and a two-hundred day simple moving average of $236.76. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. During the same period in the previous year, the firm earned $1.15 EPS. Alnylam Pharmaceuticals's quarterly revenue was down 33.3% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Raymond James raised their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a report on Friday, November 1st. HC Wainwright restated a "buy" rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Cantor Fitzgerald reissued a "neutral" rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Barclays raised their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.